Syngen Biotech Co.,Ltd.
Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sa… Read more
Syngen Biotech Co.,Ltd. (8279) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Syngen Biotech Co.,Ltd. (8279) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Syngen Biotech Co.,Ltd. - Net Assets Trend (None–None)
This chart illustrates how Syngen Biotech Co.,Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Syngen Biotech Co.,Ltd. (None–None)
The table below shows the annual net assets of Syngen Biotech Co.,Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Syngen Biotech Co.,Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Syngen Biotech Co.,Ltd. Competitors by Market Cap
The table below lists competitors of Syngen Biotech Co.,Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ATA
WAR:ATA
|
$33.04K |
|
LSL Property Services Plc
LSE:LSL
|
$33.06K |
|
Hyundai Engineering Plastics Co. Ltd.
KQ:089470
|
$33.07K |
|
HARVEY NORMAN HLDG
MU:HNN
|
$33.09K |
|
BIYK39
SA:BIYK39
|
$32.95K |
|
Philippine Stock Exchange Inc
PSE:PSE
|
$32.93K |
|
Hyperion Global Growth Companies Fund (Managed Fund)
AU:HYGG
|
$32.91K |
|
KINGFISHER - Dusseldorf Stock Exchang
DU:KFI1
|
$32.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syngen Biotech Co.,Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Syngen Biotech Co.,Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Syngen Biotech Co.,Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Syngen Biotech Co.,Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syngen Biotech Co.,Ltd. (8279) | NT$- | N/A | N/A | $32.97K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |